Venn Life Sciences Holdings Stock London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 70.19M | Sales 2024 * | 62.91M 78.79M | Capitalization | 189M 237M |
---|---|---|---|---|---|
Net income 2023 | 16M 20.04M | Net income 2024 * | 8M 10.02M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.57M | Net cash position 2024 * | 43.8M 54.86M | EV / Sales 2024 * | 2.31 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
22.3
x | Employees | - |
Yield 2023 * |
1.46% | Yield 2024 * |
0.85% | Free-Float | 60.8% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
1st Jan change | Capi. | |
---|---|---|
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.96% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |